[Treatment of fetal hemolytic disease by hemosorption].
Hemosorption was used in the combined treatment of fetal hemolytic disease (FHD) for the first time. It was demonstrated that hemosorption was a method of choice in pregnant females with manifest sensitization and a history of stillbirth resulted from an edematous type of the disease. A decrease (by a factor of 10(2) to 10(6] in the Rh antibody titers in the blood of the pregnant after hemosorption, and reversibility of echocardiographic signs of FHD, and normalized fetal cardiac performance were regarded as a beneficial prognostic sign. The authors suggested that hemosorption should be started at weeks 24-25 of pregnancy in the absence of echographic signs of the disease. The interval between the sessions should not exceed a fortnight. The treatment course should be completed 1-2 weeks prior to the labor. As part of combined treatment, hemosorption contributed to a reduction in mortality rates (from 81 to 41%) from the edematous type of the disease.
Sergienko
N S
NS
Malinovskaia
S Ia
SIa
Sichinava
L G
LG
D000328:Adult; D004899:Erythroblastosis, Fetal / Q000517:prevention & control / Q000628:therapy*; D005260:Female; D006464:Hemoperfusion; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000628:therapy*; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D011295:Prenatal Care / Q000379:methods*; D012203:Rh Isoimmunization / Q000628:therapy*
Lechenie gemoliticheskoĭ bolezni ploda metodom gemosorbtsii.